Dr. Dubensky joined our board of directors in August 2022. Dr. Dubensky was the founding chief executive officer of Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), and currently serves as the President of Tempest. Tempest is a clinical-stage biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Dr. Dubensky brings significant expertise in the discovery, development and translation of novel small molecule-, biologic- and vector-based cancer therapies, having advanced several first-in-human drug candidates. He previously held various roles leading discovery biology, development and clinical translation in cancer immunotherapy and infectious disease indications at multiple biotech companies, including Viagene, Inc., Chiron Corporation, Onyx Pharmaceuticals, Cerus Corporation and Immune Design Corp. He also has an extensive publication and patent record. Dr. Dubensky received his Bachelor of Arts degree in Bacteriology and Immunology from the University of California, Berkeley and his Ph.D. degree at the University of Colorado Health Sciences center. He conducted his post-doctoral studies at Harvard Medical School in the Department of Pathology and received executive training at the University of California, San Diego, Executive program for Scientists and Engineers.